Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Employees - 13, CEO - Shane J. Schaffer, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -14.56, Piotroski Score(max is 10): 3, Working Capital: $1636250, Total Assets: $15073263, Retained Earnings: $-132375031, EBIT: -19938108, Total Liabilities: $12564356, Revenue: $0

AryaFin Target Price - $0.39 - Current Price $ - Analyst Target Price $